ESTRELLA IMMUNOPHARMA, INC. Deferred Tax Assets, Tax Deferred Expense, Other
ESTRELLA IMMUNOPHARMA, INC. (ESLA) had Deferred Tax Assets, Tax Deferred Expense, Other of $344.35 thousand as of 2023-06-30, per its 10-Q filed 2023-08-01.
Discontinued › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsTaxDeferredExpenseOther · last filed 2023-08-01
- 2023-06-30: Deferred Tax Assets, Tax Deferred Expense, Other $344.35K.
- 2023-03-31: Deferred Tax Assets, Tax Deferred Expense, Other $318.31K.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $292.15K.
- 2021-12-31: Deferred Tax Assets, Tax Deferred Expense, Other $0.00.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Other |
|---|---|
| 2023-06-30 | $344.35K 10-Q · filed 2023-08-01 |
| 2023-03-31 | $318.31K 10-Q · filed 2023-05-18 |
| 2022-12-31 | $292.15K 10-Q · filed 2023-08-01 |
| 2021-12-31 | $0.00 10-K · filed 2023-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| BioCardia, Inc. (BCDA) | United States | $0.016B | |
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |